Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Revagenix

revagenix.com ↗

Clinical Phase 1

Profile checked Oct 10, 2026

Keywords: Non-cystic Fibrosis Bronchiectasis

1Trials (company is sponsor)

Timeline

Jul 13, 2026 Trial start 1: A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasi source ↗

Upcoming milestones

2027-06 (ESTIMATED) · 1 · A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis ( · NCT07709494

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07709494	A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa	1	Recruiting	Jul 13, 2026	2027-06 (estimated)